{
    "clinical_study": {
        "@rank": "112620", 
        "arm_group": [
            {
                "arm_group_label": "Lucentis; chemotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Lucentis: 0.5mg/0.05 ml;Other Name: Ranibizumab;monthly for the first six months.\nChemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months."
            }, 
            {
                "arm_group_label": "chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the clinical efficacy of intravitreal injections of Ranibizumab\n      (Lucentis) together with chemotherapy in the treatment of Retinoblastoma as compared to\n      chemotherapy alone."
        }, 
        "brief_title": "Efficacy Study of Lucentis in the Treatment of Retinoblastoma", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Retinoblastoma", 
        "condition_browse": {
            "mesh_term": "Retinoblastoma"
        }, 
        "detailed_description": {
            "textblock": "This study will be a phase II open label interventional case series. Patients with\n      retinoblastoma will be randomized to receive chemotherapy with or without intravitreal\n      ranibizumab at a dose of 0.5mg/0.05 ml. Patients will receive ranibizumab via a pars plana\n      injection on a monthly basis for a total duration of therapy of 6 months. Patients will be\n      followed for 24 months  ."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to provide written informed consent and comply with study assessments for the\n             full duration of the study.\n\n          -  Definite characteristic signs of retinoblastoma,Group D base on Intraocular\n             International Retinoblastoma classify, IIRC.\n\n        Exclusion Criteria:\n\n          -  History of surgical intervention for retinoblastoma in the study eye.\n\n          -  Any previous disease in the study eye.\n\n          -  Previous participation in any studies of investigational drugs within 1 month\n             preceding Day 0 (excluding vitamins and minerals).\n\n          -  Previous participation in a clinical trial (for either eye) involving anti angiogenic\n             drugs (pegaptanib, ranibizumab, anecortave acetate, protein kinase C inhibitors,\n             etc.)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01899066", 
            "org_study_id": "yanghs20130627"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lucentis; chemotherapy", 
                "description": "Lucentis:0.50mg/0.05ml, intravitreal injection,monthly for the first six months.\nchemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.", 
                "intervention_name": "Lucentis, chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": "Ranibizumab"
            }, 
            {
                "arm_group_label": "chemotherapy", 
                "description": "chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.", 
                "intervention_name": "chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": [
                    "vincristine;", 
                    "carboplatin;", 
                    "etoposide."
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Etoposide", 
                "Vincristine", 
                "Etoposide phosphate", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Efficacy", 
        "lastchanged_date": "May 10, 2014", 
        "location": {
            "contact": {
                "email": "yanghs64@126.com", 
                "last_name": "Huasheng Yang, MD,PHD", 
                "phone": "+862087331539"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "+8620"
                }, 
                "name": "Zhongshan Ophthalmic Center, Sun Yat-sen University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Lucentis in the Treatment of Retinoblastoma - A Phase II, Single Center, Randomized Study to Evaluate the Efficacy of Ranibizumab in Subjects With Retinoblastoma", 
        "overall_contact": {
            "email": "yanghs64@126.com", 
            "last_name": "Huasheng Yang, M.D, PHD", 
            "phone": "+8620-87331539"
        }, 
        "overall_official": {
            "affiliation": "Sun Yat-sen University", 
            "last_name": "Huasheng Yang", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "measure the mortality rate for the two groups(Cancer-related death and non-Cancer-related death) at two years", 
            "measure": "all cause mortality", 
            "safety_issue": "No", 
            "time_frame": "two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01899066"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Huasheng Yang", 
            "investigator_title": "Efficacy Study of Lucentis in the Treatment of Retinoblastoma", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "measure the tumor size and new vessels by ultrasonography\uff0cfundus photography and fundoscopy before each treatment, and 1,3,6,9,12,18,24 months after the treatment.", 
            "measure": "Efficacy of Lucentis(intravitreal injection) in the Treatment of Retinoblastoma", 
            "safety_issue": "No", 
            "time_frame": "two years"
        }, 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}